Início › Câncer de Pulmão de Não Pequenas Células › Flórida › Fort Lauderdale
Ensaios clínicos de Câncer de Pulmão de Não Pequenas Células em Fort Lauderdale, FL
12 estudos para Câncer de Pulmão de Não Pequenas Células estão buscando participantes em locais em Fort Lauderdale e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.
Texto oficial do estudo (Inglês)
Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RecrutandoFase 3
- Holy Cross Hospital, Fort Lauderdale
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
RecrutandoFase 3
- The Oncology Institute of Hope and Innovation - Fort Lauderdale ( Site 0156), Fort Lauderdale
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RecrutandoFase 3
- Helios Clinical Research, Fort Lauderdale
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
RecrutandoFase 2
- The Oncology Institute of Hope and Innovation 1, Fort Lauderdale
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
RecrutandoFase 2
- Holy Cross Hospital, Fort Lauderdale
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
RecrutandoFase 3
- Research Site, Fort Lauderdale
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RecrutandoFase 3
- Clinical Study Sites, Fort Lauderdale
- Clinical Study Site, Fort Lauderdale
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
RecrutandoFase 3
- Holy Cross Hospital, Fort Lauderdale
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
RecrutandoFase 3
- Broward Health, Fort Lauderdale
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
RecrutandoFase 3
- Holy Cross Hospital, Fort Lauderdale
- The Oncology Institute of Hope and Innovation, Fort Lauderdale
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
RecrutandoFase 2
- Helios Clinical Research, Fort Lauderdale
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
RecrutandoFase 1/2
- Holy Cross Hospital (site 213), Fort Lauderdale
Ensaios de Câncer de Pulmão de Não Pequenas Células em outras cidades
- Houston, TX145 estudos
- New York City, NY121 estudos
- Arlington, VA104 estudos
- Nashville, TN97 estudos
- Boston, MA90 estudos
- Los Angeles, CA87 estudos
- St. Louis, MO73 estudos
- Chicago, IL61 estudos
- Baltimore, MD60 estudos
- San Antonio, TX59 estudos
- Columbus, OH57 estudos
- Washington, DC55 estudos
Outros estudos em Fort Lauderdale
- Câncer (todos os tipos)7 estudos
- Câncer de Pulmão7 estudos
- Insuficiência Cardíaca6 estudos
- Degeneração Macular5 estudos
- Câncer de Ovário4 estudos
- Câncer de Mama4 estudos
- Mieloma Múltiplo3 estudos
- Cânceres do Sangue3 estudos
- Doença Renal Crônica3 estudos
- Doença Cardiovascular3 estudos
- Câncer de Cólon3 estudos
- Câncer Colorretal3 estudos
Fonte: ClinicalTrials.gov, dados obtidos em 6 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.